If a safe, inexpensive, once-a-day pill could substantially reduce the risk of myocardial infarction (MI) or stroke, would people want it? Most would probably say yes because MI and stroke are the first and third leading causes of death, respectively, in the United States.1 It is likely that many employers, health plans, and payers would also say yes because MI and stroke cost the US economy more than $300 billion annually in health care expenditures and lost productivity.2
Kellermann AL, Desai NR. Obstacles to Developing Cost-Lowering Health Technology: The Inventor’s Dilemma. JAMA. 2015;314(14):1447–1448. doi:10.1001/jama.2015.10114
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: